AstraZeneca Reiterates $80 Billion Revenue Goal for 2030

Tuesday, February 10, 2026 at 11:33 AM

#AstraZeneca #Growth Strategy #Pharmaceutical #Revenue Goal

AstraZeneca is forecasting steady profit growth and is confident in reaching its ambitious goal of $80 billion in annual sales by 2030, driven by new medicines and investments, despite challenges from US policies.

Markets★★Similarity: 67% · 25d ago

Societe Generale Raises 2026 Profitability Target

The bank is projecting higher revenue and lower costs, after reporting a stronger net profit for the fourth quarter.

Markets★★Similarity: 67% · 26d ago

Novartis Forecasts Profitability Hit From Generic Drug Competition in U.S.

The pharma major said it faces the largest drug-patent expiry headwind in its history this year.

Tech★★Similarity: 65% · 20d ago

Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products

The biopharmaceutical company may start to offer two cancer therapies and an additional HIV treatment option this year.

Markets★Similarity: 64% · 25d ago

Cigna Revenue Lifted by Growth in its Evernorth Unit

Cigna Group logged higher revenue in its latest quarter as its pharmacy-benefit business Evernorth continues to grow.

Data sourced from public RSS feeds and News APIs.

AstraZeneca Reiterates $80 Billion Revenue Goal for 2030

Related Articles

Societe Generale Raises 2026 Profitability Target

Novartis Forecasts Profitability Hit From Generic Drug Competition in U.S.

Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products

Cigna Revenue Lifted by Growth in its Evernorth Unit

AstraZeneca Reiterates $80 Billion Revenue Goal for 2030

Related Articles

Societe Generale Raises 2026 Profitability Target

Novartis Forecasts Profitability Hit From Generic Drug Competition in U.S.

Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products

Cigna Revenue Lifted by Growth in its Evernorth Unit